GLP-1 receptors are the target of several existing drugs prescribed for glucose-lowering in T2D which, based on studies of small-cohorts, offer potential as therapies for PPH, extending their application beyond the management of T2D. This evidence concerns the gene GLP1R and pulmonary arterial hypertension.